**IVABRADINE**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Manner of administration and formOral, 5mg tablet: film-coated | Max.Qty | №.ofRpts | Dispensed Price for Max. Qty  | Proprietary Name and Manufacturer  |
| DRUG NAME (IN CAPITALS)**IVABRADINE**{Forms(s)} {strength(s)} 5mg tablet: film-coated, 56 tablets | 1 | 5 | $56.44 | **Coralan**Servier Laboratories (Aust.) Pty Ltd  |  |
|  |
| **Category /** **Program** | General Schedule |
| **Prescriber type:** | [ ] Dental [x] Medical Practitioners [ ] Nurse practitioners [ ] Optometrists[ ] Midwives |
| **Episodicity:** | Chronic |
| **Severity:** | N/A |
| **Condition:** | heart failure |
| **PBS Indication:** | Chronic heart failure |
| **Treatment phase:** | N/A |
| **Restriction Level / Method:** | [ ] Restricted benefit[x] Authority Required - In Writing[x] Authority Required - Telephone[x] Authority Required – Emergency[x] Authority Required - Electronic[ ] Streamlined |
| **Treatment criteria:** | N/A |
| **Clinical criteria:** | * Patient must be symptomatic with NYHA classes II or III,

**AND*** Patient must be in sinus rhythm,

**AND*** Patient must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%,

**AND*** Patient must have a resting heart rate at or above 77 bpm at the time ivabradine treatment is initiated,

**AND*** Patient must receive concomitant optimal standard chronic heart failure treatment, which must include the maximum tolerated dose of a beta-blocker, unless contraindicated or not tolerated
 |
| **Population criteria:** | N/A |
| **Foreword** | N/A |
| **Definitions** | N/A |
| **Prescriber Instructions** | Resting heart rate should be measured by ECG after 5 minutes restThe ECG result must be documented in the patient's medical records when treatment is initiated. |
| **Administrative Advice** | **Continuing Therapy Only:**For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.  |
| **Cautions** | N/A |